On October 28, 2026, a new publication titled "Isotretinoin Alleviates Rosacea-like Inflammation by Partially Involving TET2 Upregulation and JAK2/STAT3 Suppression" appeared in The Journal of Investigative Dermatology. The paper is associated with research involving LL-37, a peptide studied in the context of rosacea-like inflammation. LL-37 remains classified as unapproved for research use only, with no approved clinical indications. This publication is listed under PubMed ID 42951126 and is available through PubMed's public record. The title indicates the study addresses isotretinoin's effects on rosacea-like inflammation, referencing mechanisms including TET2 upregulation and JAK2/STAT3 suppression. No specific findings, efficacy data, or outcome details beyond the title and journal listing are reported here. This brief reflects only the publication record as provided and does not summarize or interpret study results. Readers interested in the broader context of LL-37 research, including its classification and other related studies, are encouraged to consult additional sources. For further background on this compound, see the linked compound overview.
LL-37 Research Featured in Rosacea Study Published in JID
Source: https://pubmed.ncbi.nlm.nih.gov/42951126/